Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.

There were trends toward higher expression of both markers in metastases compared to primary tumors, and in patients treated with prior checkpoint blockade compared to patients without prior treatment, though these differences did not reach statistical significance (Additional file 1 : Figure S2).

also in 111,027 other papers